Qingqin Tan

Qingqin Tan

Auto-generated profile, based on publicly available information

Qingqin Tan

Department of Blood Transfusion, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, 330000, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2021 in ACS Nano
Verified
Journal Article
Closed access
BLBin Li
Bin Li
Dong WangDong Wang
Dong Wang
MLMichelle M. S. Lee
Michelle M. S. Lee
WWWei Wang
Wei Wang
QTQingqin Tan
Qingqin Tan
XHXi Huang
Xi Huang

24 August 2024 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
MIMuhammad Ijaz
Muhammad Ijaz
IHIkram Hasan
Ikram Hasan
TCTamoor Hamid Chaudhry
Tamoor Hamid Chaudhry
RHRui Huang
Rui Huang
LZLan Zhang
Lan Zhang
Bing GuoBing Guo
Bing Guo
Cancer is measured as a major threat to human life and is a leading cause of death. Millions of cancer patients die every year, although a burgeoning number of researchers have been making tremendous efforts to develop cancer medicine to fight against cancer. Owing to the complexity and heterogeneity of cancer, lack of ability to treat deep tumor tissues, and high toxicity to the normal cells, it complicates the therapy of cancer. However, bacterial derivative-mediated drug delivery has raised the interest of researchers in overcoming the restrictions of conventional cancer chemotherapy. In this review, we show various examples of tumor-targeting bacteria and bacterial derivatives for the delivery of anticancer drugs. This review also describes the advantages and limitations of delivering anticancer treatment drugs under regulated conditions employing these tumor-targeting bacteria and their membrane vesicles. This study highlights the substantial potential for clinical translation of bacterial-based drug carriers, improve their ability to work with other treatment modalities, and provide a more powerful, dependable, and distinctive tumor therapy.

12 June 2025 in Theranostics
Verified
Journal Article
Open access
PDF file
MIMuhammad Ijaz
Muhammad Ijaz
QTQingqin Tan
Qingqin Tan
YYYuqian Yan
Yuqian Yan
DZDaoming Zhang
Daoming Zhang
QCQi Chen
Qi Chen
Bing GuoBing Guo
Bing Guo
Glioblastoma (GBM), the most aggressive and lethal primary brain tumor, is characterized by its high rate of growth, high genetic diversity, and resistance to conventional therapies. Chimeric antigen receptor (CAR) T cell immunotherapy has emerged as a promising treatment option for a variety of cancers, including GBM. However, CAR T therapy use in GBM is very challenging due to the unique challenges posed by the brain tumor microenvironment, including immune suppression, antigen heterogeneity, poor CAR T cell trafficking, and the blood-brain barrier (BBB). Advances in CAR T cell engineering, antigen screening, targeted administration, image-guided CAR-T therapy and combination therapies are transforming immunotherapy for GBM.AI-driven CAR T immunotherapy optimizes GBM treatment by enhancing target identification, therapy customization, and efficacy monitoring. This review aims to highlight the challenges hindering the success of CAR T cell therapy in glioblastoma and explore innovative strategies to enhance its efficacy, ultimately paving the way for more effective and durable treatment options for glioblastoma. We hope this review will stimulate interest among researchers and expedite the clinic translation of CAR T therapy of glioblastoma.

12 October 2025 in Biomaterials
Verified
Journal Article
Closed access
CYChen Yu
Chen Yu
ZHZiwei Hu
Ziwei Hu
GHGenwen Hu
Genwen Hu
QJQingyun Jia
Qingyun Jia
YXYuchen Xiao
Yuchen Xiao
Bing GuoBing Guo
Bing Guo

5 April 2023 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
QTQingqin Tan
Qingqin Tan
ZCZhenxing Chen
Zhenxing Chen
LLLei Liu
Lei Liu
XHXi Huang
Xi Huang